HEROIC MEASURES WHEN TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES - THE ECONOMIC COST OF SURVIVAL

The survival of patients with hematologic malignancies who require adm ission to the intensive care unit (I.C.U.) is poor. The potential for cure in this group of patients necessitates aggressive treatment that can result in life-threatening complications. A medical, ethical and f inancial dilemma arises when aggressive therapy and intensive support is balanced with actual survival, meaningful survival and the financia l burden to society and the patient's family. We collected complete fi nancial information on 64 leukemia and lymphoma patients admitted for the first time to the intensive care unit (I.C.U.) at the H. Lee Moffi tt Cancer Center and Research Institute between 7/1/88 and 6/30/90. Th e charges were calculated from actual itemized statements and included all inpatient and out-patient charges. Survival was addressed by indi vidually evaluating candidate variables with parametric and non-parame tric analysis. Survival after I.C.U. admission and hospital discharge were studied as dependent variables in a stepwise multiple regression analysis. The nadir of the platelet count and albumin level prior to a nd during the I.C.U. admission significantly affected survival. During the I.C.U. admission, the BUN, serum creatinine and the need for mech anical ventilation significantly affected survival. Seventy-eight perc ent of patients survived less than five months and spent less than two and one half months at home. Fifty percent of patients expired during the I.C.U. admission. Only 3.2% of patients who had received two or m ore chemotherapeutic regimens had survived more than one year. The cos t per year of life gained for the entire group of patients was $189,33 9. The results of this study show that the majority of leukemia and ly mphoma patients who are admitted to the I.C.U. expire prior to dischar ge or spend a minimal amount of time at home prior to expiring. This s tudy suggests that the cost of meaningful survival must be borne in mi nd by physicians and should encourage them to discuss treatment option s, potential outcomes, risks and benefits so that a reasonable strateg y can be planned by the physician, patient and family prior to treatme nt.